An update on the diagnosis and treatment of vestibular schwannoma
- 7 November 2017
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Neurotherapeutics
- Vol. 18 (1), 29-39
- https://doi.org/10.1080/14737175.2018.1399795
Abstract
Introduction: Vestibular schwannomas (VS) account for approximately 85% of tumors in the cerebello-pontine angle, with a lifetime incidence of approximately 1 in 1000. Most are sporadic, with approximately 5% related to the tumor predisposition syndrome Neurofibromatosis Type 2 (NF2). The mainstays of management strategies are: observation, surgery, radiosurgery/radiotherapy and, for patients with NF2 and rapidly growing tumors or deteriorating neurologic function the targeted therapy bevacizumab. While morbidity and mortality rates related to treatment of VS have improved dramatically over the last decades, there are still significant improvements that could be made, in particular with regards to long-term facial nerve and hearing outcomes. Areas covered: The epidemiology and diagnosis of VS are discussed, followed by the different management strategies and outcomes of those for both sporadic and NF2 related tumors. An extensive literature review has been performed to inform this review article using PubMed and Google Scholar. Expert commentary: The future direction of VS management lies in obtaining longer-term follow-up data for patients with treated VS, and in improved understanding of cellular pathways and targeted therapies.Keywords
This publication has 81 references indexed in Scilit:
- Usefulness of Endoscope-Assisted Microsurgery for Removal of Vestibular SchwannomasJournal of Neurological Surgery Part B: Skull Base, 2012
- Management of Cerebrospinal Fluid Leaks After Vestibular Schwannoma SurgeryOtology & Neurotology, 2011
- Acoustic neuroma risk in relation to mobile telephone use: Results of the INTERPHONE international case–control studyCancer Epidemiology, 2011
- Tumor pseudoprogression following radiosurgery for vestibular schwannomaNeuro-Oncology, 2011
- Factors associated with preservation of facial nerve function after surgical resection of vestibular schwannomaJournal of Neuro-Oncology, 2010
- ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannomaNeuro-Oncology, 2010
- NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma GrowthMolecular and Cellular Biology, 2009
- Preservation of Facial Nerve Function after Postoperative Vasoactive Treatment in Vestibular Schwannoma SurgeryNeurosurgery, 2006
- Vasoactive treatment for hearing preservation in acoustic neuroma surgeryJournal of Neurosurgery, 2001
- Interface between the facial nerve and large acoustic neurinomas Immunohistochemical study of the cleavage plane in NF2 and non-NF2 casesJournal of Neurosurgery, 1994